Home › Trials › NCT05818150

Comparing genicular artery embolization to corticosteroid injections for knee osteoarthritis

Multicenter, PrOspective, Randomized, Controlled Trial Comparing GenIcular Artery EmbOlization Using Embosphere Microspheres to Corticosteroid iNjections for the Treatment of Symptomatic Knee Osteoarthritis: MOTION Study

Not applicable Interventional Merit Medical Systems, Inc. · NCT05818150

This study is testing whether a new treatment called genicular artery embolization can help people with knee osteoarthritis feel better compared to traditional corticosteroid injections.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment264 (estimated)
Ages21 Years and up
SexAll
SponsorMerit Medical Systems, Inc. Industry-sponsored
Locations23 sites (Washington, D.C., District of Columbia and 22 other locations)
Trial IDNCT05818150 on ClinicalTrials.gov

What this trial studies

This multicenter, prospective trial evaluates the effectiveness of genicular artery embolization (GAE) using Embosphere Microspheres versus corticosteroid injections in treating symptomatic knee osteoarthritis (OA). Participants will be randomized to receive either treatment and will be monitored over a 24-month period to assess pain relief and functional outcomes. The study aims to provide insights into the potential benefits of GAE as a novel intervention for knee OA compared to traditional steroid injections.

Who should consider this trial

Good fit: Ideal candidates are adults aged 21 and older with mild to severe knee pain that has not responded to conservative therapies for at least 90 days.

Not a fit: Patients with advanced atherosclerosis or those who have had prior knee replacement surgery in the target knee may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could offer a new, effective treatment option for patients suffering from knee osteoarthritis.

How similar studies have performed: While the approach of using GAE for knee OA is relatively novel, similar studies have shown promising results in other applications of embolization techniques.

Eligibility criteria

Show full inclusion / exclusion criteria 
Key Inclusion Criteria:

Provides written informed consent

Age ≥21 years

Mild to severe knee pain, defined as a WOMAC Pain score of ≥8 out of 20 (in the target knee)

Pain refractory to conservative therapies for at least 90 days prior to enrollment/randomization.

Kellgren-Lawrence grade 1, 2, 3 or 4

Key Exclusion Criteria:

Planned major surgical or endovascular procedures ≤ 30 days after the index procedure.

Advanced atherosclerosis

Known history of rheumatoid or infectious arthritis.

Prior knee replacement surgery of the target knee.

Where this trial is running

Washington, D.C., District of Columbia and 22 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Knee Osteoarthritisgenicular artery embolizationGAEknee embolizationknee OA
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.